BrainsWay Ltd. (BWAY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong financial performance with increased revenue, profit, and cash position. The company raised its guidance, indicating optimism. Strategic investments and regulatory advancements, particularly FDA approvals, boost confidence. Despite risks related to minority investments and FDA dependence, the Q&A responses were clear and positive, showing strong demand and strategic partnerships. Overall, the sentiment leans positive, suggesting a potential stock price increase in the short term.
Key Financial Performance
Revenue (Q4 2025) $14.5 million, a 27% increase year-over-year. This growth was attributed to strong demand and the implementation of a recurring revenue model.
Revenue (Full Year 2025) $52.2 million, a 27% increase year-over-year. The increase was driven by the recurring revenue model and higher adoption of Deep TMS systems.
Gross Profit (Q4 2025) $11.1 million, up $2.6 million from the prior year, with gross margin increasing to 76% from 75%. This was due to operational efficiency and scaling of the recurring revenue model.
Gross Profit (Full Year 2025) $39.4 million, a 28.8% increase year-over-year, with a consistent gross margin of 75%. The growth was driven by higher revenue and operational efficiency.
Sales and Marketing Expenses (Q4 2025) $5.1 million, a $0.6 million increase year-over-year, driven by targeted investments in commercial expansion and marketing programs.
Sales and Marketing Expenses (Full Year 2025) $18.9 million, a $2.7 million increase year-over-year, due to investments in commercial and marketing activities.
Research and Development Expenses (Q4 2025) $2.5 million, a $0.5 million increase year-over-year, primarily due to ongoing clinical trials and development activities.
Research and Development Expenses (Full Year 2025) $9.6 million, a $2.4 million increase year-over-year, reflecting investment in clinical trials and development.
General and Administrative Expenses (Q4 2025) $1.6 million, flat year-over-year.
General and Administrative Expenses (Full Year 2025) $6.5 million, a $0.7 million increase year-over-year, reflecting stable operational costs.
Operating Income (Q4 2025) $1.9 million, a $1.5 million increase year-over-year, driven by revenue growth and cost management.
Operating Income (Full Year 2025) $4.3 million, a $2.9 million increase year-over-year, reflecting scaling operations and disciplined cost management.
Adjusted EBITDA (Q4 2025) $2.3 million, up from $1.5 million in the prior year period, reflecting improved operational efficiency.
Adjusted EBITDA (Full Year 2025) $7 million, a 55.6% increase year-over-year, representing 13% of revenue, driven by the recurring revenue model and cost efficiency.
Net Income (Q4 2025) $2.9 million, up from $1.5 million in the prior year period, reflecting strong revenue growth and operational efficiency.
Net Income (Full Year 2025) $7.6 million, a 162% increase year-over-year, driven by revenue growth and cost management.
Remaining Performance Obligations $70 million, a 43% increase year-over-year, reflecting strong demand and long-term commitments through recurring leasing contracts.
Cash Position (End of 2025) $68 million in cash and cash equivalents, supporting growth initiatives and strategic investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA label expansion for Deep TMS system: Approved for use as an adjunct therapy for adolescents aged 15 to 21 suffering from major depressive disorder, expanding the addressable patient population.
SWIFT Deep TMS protocol: Landmark data published validating a faster treatment protocol for MDD, reducing clinic visits by 70% without compromising efficacy.
Neurolief investment: Strategic investment in Neurolief, developer of Proliv RX, a wearable brain neuromodulation platform for at-home use, with FDA approval for treatment-refractory MDD patients.
Market penetration: Less than 10% market penetration for Deep TMS, with strong demand from new facilities and patients.
Reimbursement coverage: Expanded reimbursement coverage in the U.S., including Premera Blue Cross and Highmark Blue Cross Blue Shield for accelerated Deep TMS protocol.
International expansion: Israeli Ministry of Defense approved reimbursement for Deep TMS therapy for PTSD patients in public hospitals.
Recurring revenue model: Majority of enterprise customers on long-term leasing agreements, providing revenue stability and growth potential.
Financial performance: Achieved 10 consecutive quarters of profitability, with 2025 revenue of $52.2 million (27% growth YoY) and gross margin of 75%.
Strategic investments: Minority investments in 5 mental health networks, supporting growth and patient access to Deep TMS.
Clinical research and pipeline: Ongoing studies in alcohol use disorder and PTSD, with NIH grant for AUD study and FDA submission for PTSD treatment.
Long-term vision: Aiming to integrate multiple treatment modalities across care settings, leveraging data-driven neuromodulation solutions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Supply Chain Factors: The company acknowledges risks related to shifting market conditions resulting from geopolitical supply chain factors, which could impact operations and financial performance.
Regulatory and Reimbursement Challenges: The company faces challenges in expanding reimbursement coverage and navigating regulatory pathways for new indications and protocols, which are critical for broader adoption of its Deep TMS systems.
Market Penetration and Awareness: Despite growth, the company has penetrated less than 10% of the market, indicating challenges in building awareness and adoption of Deep TMS systems.
Time and Accessibility Barriers: Patients face hurdles such as the number of required office visits for treatment, which could limit adoption and retention rates.
Economic and Health Burden of Alcohol Use Disorder: The company is addressing alcohol use disorder, a condition with high relapse rates and significant economic and health impacts, which presents challenges in achieving effective treatment outcomes.
PTSD Treatment Demand in Israel: The growing clinical need for PTSD treatment in Israel, especially following recent geopolitical events, poses challenges in meeting demand and ensuring adequate access to care.
Strategic Execution Risks: The company’s strategic initiatives, including minority equity investments in mental health providers and partnerships, carry execution risks and depend on the success of these providers to scale and deliver results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: BrainsWay expects revenue in the range of $66 million to $68 million for the full year 2026, representing a year-over-year growth rate of 27% to 30%.
Operating Income and EBITDA: The company anticipates operating income in the range of 13% to 14% of revenue and adjusted EBITDA of $12 million to $14 million, representing anticipated growth of 86% to 100% over 2025.
Market Expansion and Adoption: BrainsWay plans to expand market share by targeting less than 10% of the penetrated market, with strong demand from new facilities and patients. The company is also focusing on expanded reimbursement coverage across the U.S. and broader adoption of its Deep TMS systems.
FDA Clearances and Protocols: Recent FDA clearances include a label expansion for Deep TMS for adolescents aged 15 to 21 with major depressive disorder and an accelerated Deep TMS protocol for MDD treatment. These milestones are expected to support broader adoption and improve patient access.
Strategic Investments: BrainsWay plans to continue its minority equity investment program in high-performing mental health providers, with over 200 potential clinics identified for participation in 2026. The company also aims to develop a portfolio of data-driven, technology-enabled neuromodulation solutions.
Clinical Research and Development: The company is advancing its clinical and regulatory pathway for Deep TMS, including ongoing work in alcohol use disorder and PTSD. It is also preparing an FDA submission for depression patients with comorbid PTSD symptoms.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the fourth quarter placements, including units sold, units leased, and OCD placements?
A:95 systems were shipped during Q4, with more than 50% of these included in the [indiscernible] call.
Q:Can you elaborate on the Deep TMS 360 trial, including the number of centers involved, patient recruitment, and timeline?
A:The TMS 360 trial targets two markets: addiction and neurology. For addiction, 10 centers in the U.S. are recruiting over 200 patients for an alcohol use trial, aiming to recruit at least 50% by year-end. For neurology, 3 centers are conducting a feasibility study on Alzheimer's disease to assess the rotational field 360 machine's impact on slowing the disease.
Q:Was there any pricing adjustment in 2025, and are there plans for pricing changes in 2026 for sales or leases?
A:No pricing reductions are anticipated. Customers are willing to pay a premium for the product's value and support. The company aims to optimize pricing further.
Q:What percentage of the $70 million obligations relates to commitments from existing strategic partners?
A:The minority investment program launched in the second half of 2025 has shown strong results, with centers delivering $3 million to $5 million in yearly backlog or bookings. Utilization and demand for Deep TMS systems have exceeded expectations.
Q:Do you anticipate significant utilization of the SWIFT protocol for Deep TMS in conjunction with ketamine or psychedelics-based pharmacotherapy in MDD?
A:Yes, there is strong demand for TMS, driven by the SWIFT protocol. It is increasingly used with other modalities like psychedelics, medication management, and other therapies. Additional demand comes from OCD treatments and FDA clearance for adolescents.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were direct and detailed.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blue Cross
Health
MDD patient
Proliv RX
SWIFT protocol
ability
access treatment
adolescent
adoption
adult
approach
capital
care
core
coverage
decision
demand
depression patient
efficacy
equity
investment health
leasing
milestone
need
payer
policy
population
profitability
protocol treatment
psychiatry
research
setting
step access
study
success
therapy
treatment MDD
treatment option
visit
way
work
BWAY Transcript
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary presents a mixed picture. Financially, there's a positive increase in revenue and gross margin, along with a reduced net loss, indicating operational improvements. However, geopolitical risks and potential supply chain disruptions pose significant threats. The lack of strategic initiatives or operational updates in the call and stable cash reserves suggest limited immediate growth catalysts. Without market cap data, it's prudent to predict a neutral stock price movement, considering both positive financials and external risks.
BrainsWay Ltd. (BWAY) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call summary and Q&A reveal strong financial performance with increased revenue, profit, and cash position. The company raised its guidance, indicating optimism. Strategic investments and regulatory advancements, particularly FDA approvals, boost confidence. Despite risks related to minority investments and FDA dependence, the Q&A responses were clear and positive, showing strong demand and strategic partnerships. Overall, the sentiment leans positive, suggesting a potential stock price increase in the short term.
BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript
Positive11-11
The company demonstrates strong financial performance with increased revenue, gross profit, and net profit. The positive cash flow and substantial cash reserves further enhance financial stability. The raised revenue guidance and promising market expansion initiatives are optimistic. The Q&A section reveals potential growth through accelerated protocols and minority investments, despite some management ambiguity. Overall, the company's strategic investments and market expansion efforts indicate a positive outlook, likely resulting in a stock price increase within the 2% to 8% range.
BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call presented strong financial performance with a 26% revenue increase, robust gross profit margins, and a significant net profit rise. The Q&A section highlighted positive developments like potential FDA clearance, strategic financing, and successful collaborations. Despite increased expenses, efficient cost management and strong cash position support financial health. The reiterated revenue guidance and strategic expansions further bolster a positive outlook. Given these factors, the stock price is likely to experience a positive movement in the short term.
BWAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
